Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaTH Forward trial of TransCon PTH in adults with hypoparathyroidism
2024-512967-29-00Phase 2Completed
- Sponsor
- Ascendis Pharma
- Start
- Jul 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in hypoparathyroidism comparing TransCon PTH with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint at Week 4. Started Jul 2024; status: completed.
02
Drugs
palopegteriparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on 2024-512967-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512967-29-00.